A prospective proof-of-concept study by Nicolau et al 19 found that liraglutide treatment for three months resulted in a decrease in BMI (from 39.3 to 35.6 kg/m 2 ), waist circumference (from 121.3 to 110.6 cm), mean Hurley stage (from 2.6 to 1.1), DLQI (from 12.3 to 9.7), Beck Depression Inventory (BDI) (from 22 to 16.7), and visual analog scale (VAS) for pain (from 5.6 to 3.2), as well as a decrease in inflammatory markers such as CRP (from 4.5 to 3 mg/dL), homocysteine (from 16.2 to 13.3 mol/L), plasma morning cortisol (from 15.9 to 12.6 g/dL), and insulin (from 18.9 to 15.7 U/mL)
10.1142/S0192415X21500579 [DOI] [PubMed] [Google Scholar] Zhang B., Zhang X., Zhang C., Sun G., Sun X
Patient education regarding expected versus concerning symptoms plays a crucial role in medication adherence and overall treatment success
Significantly lower activities of liver SOD were observed in METH group as compared to the normal control group
GLP-1 medication is a convenient solution that aids appetite suppression and promotes significant weight loss over time
Indications and Usage for Januvia JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
